HISTORY OF CONDITIONAL GRANTS OF SHARES (ACAS) TO MR JEAN-PAUL AGON SINCE HIS APPOINTMENT AS A CORPORATE OFFICER
| Grant date | Number of ACAs granted | Performance conditions(3)See the performance conditions described in chapter 7 of this document. | Grant value (IFRS fair value) | Date of final vesting of all or part of the ACAs | Number of finally vested shares | First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions. |
|---|---|---|---|---|---|---|
|
17 April 2012At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. |
17 April 2012At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of ACAs granted50,000 |
17 April 2012At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
17 April 2012At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Grant value (IFRS fair value)3,853,500 |
17 April 2012At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Date of final vesting of all or part of the ACAs18 April 2016 |
17 April 2012At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of finally vested shares50,000 |
17 April 2012At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.18 April 2018 |
|
26 April 2013 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. |
26 April 2013 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of ACAs granted40,000 |
26 April 2013 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
26 April 2013 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Grant value (IFRS fair value)4,494,800 |
26 April 2013 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Date of final vesting of all or part of the ACAs27 April 2017 |
26 April 2013 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of finally vested shares40,000 |
26 April 2013 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.27 April 2019 |
|
17 April 2014 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. |
17 April 2014 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of ACAs granted40,000 |
17 April 2014 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
17 April 2014 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Grant value (IFRS fair value)4,183,200 |
17 April 2014 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Date of final vesting of all or part of the ACAs18 April 2018 |
17 April 2014 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of finally vested shares40,000 |
17 April 2014 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.18 April 2020 |
|
22 April 2015 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. |
22 April 2015 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of ACAs granted32,000 |
22 April 2015 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
22 April 2015 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Grant value (IFRS fair value)5,167,680 |
22 April 2015 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Date of final vesting of all or part of the ACAs23 April 2019 |
22 April 2015 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. Number of finally vested shares26,432 |
22 April 2015 (1)At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two-year period during which the shares may not be transferred. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.23 April 2021 |
|
20 April 2016 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. |
20 April 2016 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of ACAs granted32,000 |
20 April 2016 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
20 April 2016 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Grant value (IFRS fair value)4,938,240 |
20 April 2016 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Date of final vesting of all or part of the ACAs21 April 2020 |
20 April 2016 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of finally vested shares32,000 |
20 April 2016 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.21 April 2020 |
|
20 April 2017 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. |
20 April 2017 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of ACAs granted32,000 |
20 April 2017 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
20 April 2017 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Grant value (IFRS fair value)5,340,800 |
20 April 2017 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Date of final vesting of all or part of the ACAs21 April 2021 |
20 April 2017 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of finally vested shares26,544 |
20 April 2017 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.21 April 2021 |
|
17 April 2018 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. |
17 April 2018 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of ACAs granted30,000 |
17 April 2018 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
17 April 2018 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Grant value (IFRS fair value)5,285,100 |
17 April 2018 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Date of final vesting of all or part of the ACAs18 April 2022 |
17 April 2018 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of finally vested shares30,000 |
17 April 2018 (2)The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.18 April 2022 |
|
18 April 2019 (2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. |
18 April 2019 (2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of ACAs granted24,000 |
18 April 2019 (2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Performance conditions(3)See the performance conditions described in chapter 7 of this document.Yes |
18 April 2019 (2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Grant value (IFRS fair value)5,430,000 |
18 April 2019 (2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Date of final vesting of all or part of the ACAs19 April 2023 |
18 April 2019 (2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. Number of finally vested shares24,000 |
18 April 2019 (2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period. First possible date of sale of a portion of these(4)Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.19 April 2023 |
(1) At the end of the vesting period, Mr Jean-Paul Agon, as a French resident on the date of granting the shares, is required to hold the fully vested shares for an additional two year period during which the shares may not be transferred.
(2) The 20 April 2016, 20 April 2017, 17 April 2018 and 18 April 2019 Plans set a four-year vesting period, without any holding period.
(3) See the performance conditions described in chapter 7 of this document.
(4) Mr Jean-Paul Agon, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his duties. Mr Jean-Paul Agon has undertaken not to enter into any risk hedging transactions.
TABLE OF PERFORMANCE SHARES THAT BECAME AVAILABLE DURING THE 2023 FINANCIAL YEAR FOR MR JEAN‑PAUL AGON
N/A.
| 2023 | 2022 | |||
|---|---|---|---|---|
| In € | Amounts | Amounts paid | Amounts | Amounts paid |
|
Fixed remuneration |
2,000,000 |
2,000,000 |
2,000,000 |
2,000,000 |
|
Annual variable remuneration |
2,250,000 |
2,260,000 |
2,260,000 |
2,260,000 |
|
Exceptional remuneration |
- |
- |
- |
- |
|
Remuneration for term of office as Director |
- |
- |
- |
- |
|
Benefits in kind |
- |
- |
- |
- |
|
TOTAL |
4,250,000 |
4,260,000 |
4,260,000 |
4,260,000 |
SUMMARY TABLE OF REMUNERATION AND PERFORMANCE SHARES AWARDED TO M NICOLAS HIERONIMUS, CHIEF EXECUTIVE OFFICER
| In € | 2023 | 2022 |
|---|---|---|
|
Remuneration due in respect of the financial year |
Remuneration due in respect of the financial year 20234,250,000 |
Remuneration due in respect of the financial year 20224,260,000 |
|
Value of performance shares granted during the financial year |
Value of performance shares granted during the financial year 20236,323,320 |
Value of performance shares granted during the financial year 20226,066,600 |
| TOTAL | TOTAL202310,573,320 | TOTAL202210,326,600 |
HISTORY OF THE STOCK OPTIONS GRANTED TO MR NICOLAS HIERONIMUS SINCE HIS APPOINTMENT AS A CORPORATE OFFICER THAT CAN STILL BE EXERCISED AT 31 DECEMBER 2023
N/A.
TABLE OF SHARE SUBSCRIPTION OR PURCHASE OPTIONS EXERCISED BY MR NICOLAS HIERONIMUS DURING FINANCIAL YEAR 2023
N/A.
